Zhen Wang is a partner of Global Law Office based in Beijing and Suzhou. He focuses on capital markets, M&A, private equity and venture capital, and ongoing corporate advice. Combining legal and industry expertise in semiconductors, healthcare and other technology-intensive sectors, he advises innovative businesses on early-stage financing, ownership structures, equity incentives, corporate governance, listings, M&A, refinancings and reorganizations. He has led or participated in dozens of domestic and cross-border corporate and capital markets projects in semiconductors, life sciences and healthcare, advanced manufacturing and TMT.

In capital markets, Zhen Wang has led or participated in A-share IPO or National Equities Exchange and Quotations (NEEQ) listing projects for Suzhou Sepax Technologies Co., Ltd. (688758.SH), Bestlink Technologies Co., Ltd. (603206.SH), StarPower Semiconductor Ltd. (603290.SH), Guizhou BC&TV Information Network Co., Ltd. (600996.SH), Shenzhen Easttop Supply Chain Management Co., Ltd. (002889.SZ), Tibet Duo Rui Pharmaceutical Co., Ltd. (301075.SZ), Shanghai Hysea Industrial Communication Co., Ltd. (920405), China DaaS Technology Co., Ltd. (passed listing committee review), Taiying Technology Group Co., Ltd., Hebei Yinghu Agricultural Machinery Co., Ltd., Tourism & Investment Development Co., Ltd. of Hubei, Hubei Jiaotou Intelligent Testing Co., Ltd. (874416) and Hebei Xingtai Rural Commercial Bank Company Limited (873041), as well as  H-share IPO projects for LongBio Pharma (Suzhou) Co., Ltd. and GeneQuantum Healthcare. His listed-company refinancing experience includes convertible bond offerings and private placements for StarPower Semiconductor Ltd. (603290.SH), Tecon Biology Co., Ltd. (002100.SZ), Geron Co., Ltd. (002722.SZ), Great Wall Motor Company Limited (601633.SH; 02333.HK) and Shandong Qixing Iron Tower Co., Ltd. (002359.SZ).

In listed-company M&A and restructurings, Zhen Wang has represented acquirers, listed companies or target companies in transactions including the major asset restructuring of Dongfeng Electronic Technology Co., Ltd. (600081.SH) through a reverse merger by absorption and an acquisition of assets through a share issuance; the backdoor listing of Zhengzhou Yutong Heavy Industries Co., Ltd. through Zhengzhou Deheng Hongsheng Technology Co., Ltd. (600817.SH); the acquisition of semiconductor equipment company Wisdom Semiconductor Technology Co., Ltd. by Dalian Bio-Chem Company Limited (603360.SH) as part of its diversification into a new sector; Zodigrand Group Co., Ltd.'s acquisition of control of Soft Rock (000609.SZ); and Tibet Dejin Enterprise Management Co., Ltd.'s acquisition of control of, and tender offer for, Shanghai Huitong Energy Co., Ltd. (600605.SH). Other transactions include the acquisition of control of Bringspring Science and Technology Co., Ltd. (300290.SZ) by a provincial-level state-owned enterprise in Henan; StarPower Semiconductor Ltd.'s (603290.SH) acquisition of control of Meiken Semiconductor Technology Co., Ltd., a subsidiary of Midea Group; Shanghai Kelai Mechatronics Engineering Co., Ltd.'s (603960.SH) acquisition of control of Shanghai Eline Technology Co., Ltd.; and the strategic cash investment by Zhiyang Innovation Technology Co., Ltd. (688191.SH) in Adaps Photonics.

In private equity and venture capital, Zhen Wang has advised investment institutions including China-U.S. Green Fund, Feng Yuan (Ningbo) Private Equity Fund Management Co., Ltd., China Development Bank Capital Co., Ltd., Macquarie, Hony Capital, BOCOM International Holdings and Vatti Capital on fund formation, domestic and overseas investments, acquisitions and exits. He has also led or participated in equity financings for technology businesses including Nova Fusion Energy Technology (Shanghai) Co., Ltd., Antitumor and Health Reconstruction Biotechnology Co., Ltd., Wisdom SemiTeC (Jiangsu) Technology Co., Ltd., Anhui Dongfang Lichuan Environmental Protection Technology Co., Ltd., Hemu Biotechnology Co., Ltd., Jiangsu Hangyuan New Technology Co., Ltd., Wuhan Conform Pharmaceutics Co., Ltd., Guangdong Zhidong Future Technology Co., Ltd., MRG Semitech Co., Ltd. and Beijing Quanshi Soft Crystal Biotechnology Co., Ltd.

In equity incentives, employee share ownership and ownership structuring, Zhen Wang has advised StarPower Semiconductor Ltd. (603290.SH), Zhejiang Benli Technology Co., Ltd. (301065.SZ), Hubei Wanrun New Energy Technology Co., Ltd. (688275.SH), Shanghai Techsense Co., Ltd., Lenovo Netapp Technology Limited, China DaaS Technology Co., Ltd., China National Pharmaceutical Group Animal Health Co., Ltd., Wuhan Conform Pharmaceutics Co., Ltd., Hubei Weisen Pharmaceutical Co., Ltd. and Sichuan Ziren Pharmaceutical Co., Ltd. on establishing employee shareholding vehicles, designing restricted stock and share option plans, and restructuring share ownership.

His ongoing and special-purpose corporate advisory clients have included StarPower Semiconductor Ltd. (603290.SH), Guizhou BC&TV Information Network Co., Ltd. (600996.SH), Hengtong Logistics Co., Ltd. (603223.SH), Beijing Zodi Investment Co., Ltd. (000609.SZ), Shenzhen Easttop Supply Chain Management Co., Ltd. (002889.SZ), Genimous Technology Co., Ltd. (000676.SZ), China Certification & Inspection Group, Dongfeng Motor Co., Ltd. and Mayinglong Pharmaceutical Group Co., Ltd. (600993.SH).

2026-Present  Global Law Office, Partner

2024-2026  Hai Run Law Firm, Partner

2015-2024  Zhong Lun Law Firm, Associate; Salaried Partner

Admitted in the PRC in 2018

2015  China University of Political Science and Law, Master’s degree in Law and Economics

2024-2025  Fudan University, Practical Entrepreneurship Program in Biomedicine and Healthcare (undertaken while working)

Selected in 2024 for the panel of project review experts of the Anhui Provincial Department of Economy and Information Technology.